CME - New Amsterdam Pharma

The following information is designed for healthcare professionals in the United States.

Please confirm you are a U.S. healthcare professional.

YES, I AM NO, I AM NOT

The content of this is intended only for US healthcare professionals licensed to practice in the United States. This resource is intended to provide balanced, scientific, and evidence-based information in response to physician request. Content may include information on investigational agents that have not been approved by the US Food and Drug Administration and may include content and statements beyond approved labeling for some products. These slides are not accredited continuing medical education.

MRC CME

This content has been independently developed and is accredited continuing medical education (CME) appearing on external sites not controlled by NewAmsterdam Pharma B.V.

External links are provided for informational purposes only and do not constitute endorsements or responsibility by NewAmsterdam Pharma B.V.

Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction

Learn More

Reexamining CETP Inhibition to Reduce CVD in High-risk Populations: A Focus on LDL-C Reduction

Learn More

CETP Inhibitors: On the Horizon for Cardiovascular Risk Reduction

Learn More